{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:33:01Z","timestamp":1792715581410,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.ejps.2014.10.015","type":"journal-article","created":{"date-parts":[[2014,10,25]],"date-time":"2014-10-25T11:03:00Z","timestamp":1414234980000},"page":"173-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"special_numbering":"C","title":["Development, in vitro and in vivo characterization of zoledronic acid functionalized hydroxyapatite nanoparticle based formulation for treatment of osteoporosis in animal model"],"prefix":"10.1016","volume":"66","author":[{"given":"Deepak Kumar","family":"Khajuria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rema","family":"Razdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debiprosad Roy","family":"Mahapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2014.10.015_b0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1023\/A:1008993814033","article-title":"An in vivo study on the reaction of hydroxyapatite-sol injected into blood","volume":"11","author":"Aoki","year":"2000","journal-title":"J. Mater. Sci. Mater. Med."},{"key":"10.1016\/j.ejps.2014.10.015_b0005","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.biomaterials.2003.08.073","article-title":"In vivo behavior of three different injectable hydraulic calcium phosphate cements","volume":"25","author":"Apelt","year":"2004","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejps.2014.10.015_b0020","first-page":"112","article-title":"Adsorption of fibronectin on hydroxyapatite functionalized with alendronate","volume":"49","author":"Becerril","year":"2013","journal-title":"J. Aust. Ceram. Soc."},{"key":"10.1016\/j.ejps.2014.10.015_b0015","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2014.10.015_b0025","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.biomaterials.2007.10.040","article-title":"Alendronate hydroxyapatite nanocomposites and their interaction with osteoclasts and osteoblast-like cells","volume":"29","author":"Boaninia","year":"2008","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejps.2014.10.015_b0035","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jmatprotec.2007.10.004","article-title":"Preparation and bioactivity evaluation of bone-like hydroxyapatite nanopowder","volume":"202","author":"Fathia","year":"2008","journal-title":"J. Mater. Proc. Technol."},{"key":"10.1016\/j.ejps.2014.10.015_b0040","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/00044011-200727040-00001","article-title":"Prevention of osteoporosis: four-year follow-up of a cohort of postmenopausal women treated with an ossein-hydroxyapatite compound","volume":"27","author":"Fernandez-Pareja","year":"2007","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.ejps.2014.10.015_b0045","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1002\/cphc.201200080","article-title":"Recent advances in research applications of nanophase hydroxyapatite","volume":"13","author":"Fox","year":"2012","journal-title":"ChemPhysChem"},{"key":"10.1016\/j.ejps.2014.10.015_b0050","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijpharm.2006.09.035","article-title":"Evaluation of nanoparticles loaded with benzopsoralen in rat peritoneal exudate cells","volume":"332","author":"Gomes","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2014.10.015_b0055","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijpharm.2006.11.024","article-title":"Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro","volume":"331","author":"Hengst","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2014.10.015_b0070","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.ejps.2014.10.015_b0075","first-page":"175","article-title":"Skeletal response of ovariectomized rats to low and high doses of 17b-estradiol","volume":"1991","author":"Kalu","year":"1991","journal-title":"Bone Miner."},{"key":"10.1016\/j.ejps.2014.10.015_b0080","first-page":"365","article-title":"Drugs for the management of osteoporosis: a review","volume":"51","author":"Khajuria","year":"2011","journal-title":"Rev. Bras. Reumatol."},{"key":"10.1016\/j.ejps.2014.10.015_b0085","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1590\/S0482-50042012000300016","article-title":"Description of a new method of ovariectomy in female rats","volume":"52","author":"Khajuria","year":"2012","journal-title":"Rev. Bras. Reumatol."},{"key":"10.1016\/j.ejps.2014.10.015_b0090","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1007\/s00776-013-0433-y","article-title":"Osteoprotective effect of propranolol in ovariectomized rats: a comparison with zoledronic acid and alfacalcidol","volume":"18","author":"Khajuria","year":"2013","journal-title":"J. Orthop. Sci."},{"key":"10.1016\/j.ejps.2014.10.015_b0095","first-page":"968","article-title":"Comparative evaluation of zoledronic acid, alfacalcidol, and propranolol in pharmacological correction of experimental osteoporosis","volume":"32","author":"Khajuria","year":"2013","journal-title":"Lat. Am. J. Pharm."},{"key":"10.1016\/j.ejps.2014.10.015_b0100","first-page":"10","article-title":"Prophylactic effects of propranolol versus standard therapy on a new model of disuse osteoporosis in rats","author":"Khajuria","year":"2013","journal-title":"Sci. Pharm."},{"key":"10.1016\/j.ejps.2014.10.015_b0105","first-page":"10","article-title":"Zoledronic acid in combination with alfacalcidol has additive effects on trabecular microarchitecture and mechanical properties in osteopenic ovariectomized rats","author":"Khajuria","year":"2014","journal-title":"J. Orthop. Sci."},{"key":"10.1016\/j.ejps.2014.10.015_b0110","doi-asserted-by":"crossref","first-page":"586431","DOI":"10.1155\/2014\/586431","article-title":"The combination therapy with zoledronic acid and propranolol improves the trabecular microarchitecture and mechanical property in an rat model of postmenopausal osteoporosis","volume":"2014","author":"Khajuria","year":"2014","journal-title":"J. Osteoporos."},{"key":"10.1016\/j.ejps.2014.10.015_b0115","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.jbiomech.2008.03.017","article-title":"Biomechanical testing in experimental bone interventions\u2014May the power be with you","volume":"41","author":"Leppanen","year":"2008","journal-title":"J. Biomech."},{"key":"10.1016\/j.ejps.2014.10.015_b0120","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jbm.a.31994","article-title":"Study of hydroxyapatite osteoinductivity with an osteogenic differentiation of mesenchymal stem cells","volume":"89","author":"Lin","year":"2009","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.ejps.2014.10.015_b0125","first-page":"474","article-title":"Toxicity of hydroxyapatite nanoparticles on rabbits","volume":"34","author":"Liu","year":"2005","journal-title":"Wei Sheng Yan Jiu"},{"key":"10.1016\/j.ejps.2014.10.015_b0130","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jconrel.2005.05.025","article-title":"On the study of BSA-loaded calcium-deficient hydroxyapatite nano-carriers for controlled drug delivery","volume":"107","author":"Liu","year":"2005","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.ejps.2014.10.015_b0135","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/jbm.a.30792","article-title":"Adsorption of bisphosphonate onto hydroxyapatite using a novel co-precipitation technique for bone growth enhancement","volume":"79","author":"McLeod","year":"2006","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.ejps.2014.10.015_b0060","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11051-007-9239-1","article-title":"Exploiting the high-affinity phosphonate\u2013hydroxyapatite nanoparticle interaction for delivery of radiation and drugs","volume":"10","author":"Ong","year":"2008","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.ejps.2014.10.015_b0140","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0142-9612(02)00438-6","article-title":"Histological evaluation of the bone response to calcium phosphate cement implanted in cortical bone","volume":"24","author":"Ooms","year":"2003","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejps.2014.10.015_b0145","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.beem.2008.07.001","article-title":"Bisphosphonates: how do they work?","volume":"22","author":"Papapoulos","year":"2008","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejps.2014.10.015_b0150","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2217\/17435889.4.2.161","article-title":"A novel biomaterial for osteotropic drug nanocarriers: synthesis and biocompatibility evaluation of a PLGA-ALE conjugate","volume":"4","author":"Pignatello","year":"2009","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.ejps.2014.10.015_b0155","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s00198-004-1595-4","article-title":"Basic fibroblast growth factor has rapid bone anabolic effects in ovariectomized rats","volume":"15","author":"Power","year":"2004","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.ejps.2014.10.015_b0160","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jpba.2005.04.012","article-title":"A validated stability indicating ion-pair RP-LC method for zoledronic acid","volume":"39","author":"Rao","year":"2005","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2014.10.015_b0165","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/187231207779814382","article-title":"Drug confinement and delivery in ceramic implants","volume":"1","author":"Regi","year":"2007","journal-title":"Drug Metab. Lett."},{"key":"10.1016\/j.ejps.2014.10.015_b0170","doi-asserted-by":"crossref","first-page":"6222s","DOI":"10.1158\/1078-0432.CCR-06-0843","article-title":"Molecular mechanisms of action of bisphosphonates: current status","volume":"12","author":"Roelofs","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2014.10.015_b0175","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ocl.2013.01.001","article-title":"Bisphosphonate therapy and atypical fractures","volume":"44","author":"Saleh","year":"2013","journal-title":"Orthop. Clin. North Am."},{"key":"10.1016\/j.ejps.2014.10.015_b0180","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3181\/0803-RM-93","article-title":"Methanolic extract of Cuminum cyminum inhibits ovariectomy-induced bone loss in rats","volume":"233","author":"Shirke","year":"2008","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.ejps.2014.10.015_b0185","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3949\/ccjm.75.10.739","article-title":"Using biochemical markers of bone turnover in clinical practice","volume":"75","author":"Singer","year":"2008","journal-title":"Cleve. Clin. J. Med."},{"key":"10.1016\/j.ejps.2014.10.015_b0195","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/0885328211424623","article-title":"Bone substitute materials delivering zoledronic acid: physicochemical characterization, drug load, and release properties","volume":"27","author":"Sorensen","year":"2013","journal-title":"J. Biomater. Appl."},{"key":"10.1016\/j.ejps.2014.10.015_b0190","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1016\/j.transproceed.2008.07.096","article-title":"The upregulation of osteoblast marker genes in mesenchymal stem cells prove the osteoinductivity of hydroxyapatite\/tricalcium phosphate biomaterial","volume":"40","author":"Sun","year":"2008","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.ejps.2014.10.015_b0200","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.actbio.2009.12.014","article-title":"Polymeric micelle-templated synthesis of hydroxyapatite hollow nanoparticles for a drug delivery system","volume":"6","author":"Ye","year":"2010","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ejps.2014.10.015_b0205","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1248\/bpb.30.898","article-title":"Short-to mid term effects of ovariectomy on bone turnover, bone mass and bone strength in rats","volume":"30","author":"Zhang","year":"2007","journal-title":"Biol. Pharm. Bull."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098714004096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098714004096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T03:22:15Z","timestamp":1538104935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098714004096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":39,"alternative-id":["S0928098714004096"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2014.10.015","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development, in vitro and in vivo characterization of zoledronic acid functionalized hydroxyapatite nanoparticle based formulation for treatment of osteoporosis in animal model","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2014.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}